Filing Details
- Accession Number:
- 0001140361-15-028592
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-07-24 16:38:34
- Reporting Period:
- 2015-07-22
- Filing Date:
- 2015-07-24
- Accepted Time:
- 2015-07-24 16:38:34
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 946486 | Discovery Laboratories Inc | DSCO | Biological Products, (No Disgnostic Substances) (2836) | 943171943 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1499834 | A John Tattory | 2600 Kelly Rd Suite 100 Warrington PA 18976 | Svp & Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2015-07-22 | 8,333 | $0.00 | 15,000 | No | 4 | P | Direct | |
| Common Stock | Acquisiton | 2015-03-31 | 2,458 | $1.19 | 37,087 | No | 5 | A | Indirect | By Trust |
| Common Stock | Acquisiton | 2015-06-30 | 4,301 | $0.68 | 41,388 | No | 5 | A | Indirect | By Trust |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct | |
| No | 5 | A | Indirect | By Trust |
| No | 5 | A | Indirect | By Trust |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A Warrants (Right to Buy) | Acquisiton | 2015-07-22 | 8,333 | $0.00 | 8,333 | $0.70 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 8,333 | 2015-07-22 | 2022-07-22 | No | 4 | P | Direct |
Footnotes
- Common Stock in connection with the purchase of Series A units acquired in an underwritten public offering of Series A units and Series B units with a unit purchase price of $0.60. Each Series A unit consists of one share of common stock and one Series A warrant to purchase one share of common stock at an initial exercise price of $0.70 per share. Refer to Table II for related Series A warrant information.
- Transaction reported on Table I represents Issuer's matching stock contribution pursuant to 401(k) plan.
- Series A Warrants in connection with the purchase of Series A units acquired in an underwritten public offering of Series A units and Series B units with a unit purchase price of $0.60. Each Series A unit consists of one share of common stock and one Series A warrant to purchase one share of common stock at an initial exercise price of $0.70 per share. Refer to Table I for related common stock information.
Billionaire Hedge Funds
